RVTY

SEC Filing Summary: PerkinElmer, Inc. (10-Q)

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 29, 2008. The registrant is PerkinElmer, Inc. (Note: The input metadata lists "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc., which later became Revvity). The company operates in two primary segments: Life and Analytical Sciences and Optoelectronics. The report includes unaudited condensed consolidated financial statements.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 21% ($91.3 million) for the quarter and 20% ($170.8 million) for the six months compared to the prior year periods. Growth was driven by acquisitions (approx. 5%) and favorable foreign exchange rates (approx. 5%), alongside organic growth in genetic screening and specialty lighting.
• Profitability: Net income decreased 29% for the quarter and 9% for the six months. This decline is primarily attributed to a $6.8 million loss on the disposition of discontinued operations (ViaCyte and Cellular Therapy Technology businesses) in the current quarter, compared to a gain in the prior year.
• Segment Performance:
  • Life and Analytical Sciences: Sales up 22% (quarter) and 20% (six months). Operating income decreased 20% for the quarter due to higher amortization and marketing expenses, though it remained flat for the six months.
  • Optoelectronics: Sales up 19% (quarter) and 20% (six months). Operating income increased significantly (83% for the quarter) driven by volume and productivity improvements in the amorphous silicon business.
• Acquisitions: The company completed four acquisitions in the first half of 2008: VaConics Lighting ($3.9M), LabMetrix ($4.3M), PKI Genetics ($66.3M), and ViaCell (completed late 2007, integration ongoing). Total cash used for acquisitions in the six months was approximately $74.8 million.

Guidance, Outlook, Risks, and Unusual Items

• Discontinued Operations: The company closed the ViaCyte and Cellular Therapy Technology businesses in Q2 2008, recording a pre-tax loss of $8.5 million for severance and facility closure costs. These are classified as discontinued operations.
• Debt and Liquidity: In May 2008, the company issued $150 million in 6% senior subordinated notes due in 2015. Proceeds were used to repay borrowings under the revolving credit facility. The company maintains a $650 million revolving credit facility with $265 million available.
• Restructuring: The company recorded a net reversal of restructuring and lease charges of $0.3 million for the quarter, primarily due to a lease reversal related to a 2001 divestiture. Remaining restructuring liabilities are approximately $9.2 million.
• Legal Contingencies:
  • Enzo Biochem: Ongoing litigation regarding patent infringement and breach of contract; summary judgment motions pending.
  • PharmaStem: The company secured a favorable appellate court decision in "PharmaStem I" (patents invalid/non-infringement), which was upheld by the Supreme Court. "PharmaStem II" proceedings are stayed pending PTO reexamination.
• Market Risks: The company faces risks related to foreign currency exchange (63% of business outside the U.S.), interest rate fluctuations on variable debt, and potential impairment of intangible assets ($1.9 billion net).

Investor Verification Checklist

• Verify the impact of the $8.5 million pre-tax loss from discontinued operations on the full-year earnings outlook.
• Confirm the integration progress and revenue contribution of the ViaCell and PKI Genetics acquisitions.
• Monitor the status of the Enzo Biochem litigation and potential financial exposure.
• Review the company's ability to maintain debt covenants given the increased leverage from the new $150 million note issuance.
• Assess the sustainability of the Optoelectronics segment's margin expansion amidst inflation and freight cost pressures.